Hannah Wei's questions to Ultragenyx Pharmaceutical Inc (RARE) leadership • Q2 2025
Question
On behalf of Debjit, Hannah Wei of Guggenheim Partners asked for clarification on which specific bisphosphonate therapies patients in the OI program were on before entering the study.
Answer
Emil Kakkis, Founder, President & CEO, did not disclose the specific types of bisphosphonates used. However, he confirmed that a large fraction of the study participants, greater than 90%, had been on some form of bisphosphonate therapy prior to enrollment, reflecting the study's inclusion of patients with higher fracture rates.